<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053843</url>
  </required_header>
  <id_info>
    <org_study_id>MeDiet+EVOO after AF ablation</org_study_id>
    <nct_id>NCT03053843</nct_id>
  </id_info>
  <brief_title>Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial</brief_title>
  <acronym>PREDIMAR</acronym>
  <official_title>Randomized Trial of Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de investigación HM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Virgen de las Nieves</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de investigación HM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia and represents a
      high priority public health problem, as in a few decades it will become a possibly
      unsustainable load for the national health system. Preventive and therapeutic strategies
      based on the best possible scientific evidence are required. Ablation therapy, despite being
      the most effective approach, is associated with a 30-35% arrhythmic recurrence rate. An
      intervention with Mediterranean diet and extra virgin olive oil (EVOO) has proven effective
      in primary prevention and reduced the incidence of AF in high-risk subjects in a recent,
      large, randomized trial (PREDIMED).

      Methods: Parallel, randomized, multicenter nutritional intervention trial in 640 patients
      with AF treated with catheter ablation. Two groups will be randomized in a 1:1 ratio: 1)
      intervention with Mediterranean diet and EVOO; 2) usual care (control group). The primary
      objective will be the incidence of atrial tachyarrhythmias for two years after ablation. At
      least 190 recurrences are expected after 2 years (median) of follow-up. A relative risk of
      0.7 is assumed and statistical power of 80%. Follow-up visits will be scheduled at 3, 6, 12,
      18 and 24 months. In addition to the in-person visits, event monitors will be used to
      document episodes. Dietary intervention will be carried out by nutritionists who will use
      methods adapted from the PREDIMED trial with contacts every 2 months. 1 liter of EVOO per
      week will be provided for free in the intervention arm. Inflammatory markers will be analyzed
      in both groups during follow-up. Cox models will be used to estimate adjusted hazard ratios.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 6, 2017</start_date>
  <completion_date type="Anticipated">March 6, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>atrial tachyarrhythmias documented by electrocardiogram or recorder device</measure>
    <time_frame>mean follow up of 2 years</time_frame>
    <description>Atrial tachyarrhythmia is defined at any fast rate (&gt;100 bpm) of supraventricular origin lasting more than 30 seconds and that is documented by ECG, Holter or event monitor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation documented by electrocardiogram or recorder device</measure>
    <time_frame>mean follow up of 2 years</time_frame>
    <description>AF is defined at any irregular atrial rhythm lasting more than 30 seconds and that is documented by ECG, Holter or event monitor. AF may or may not be symptomatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Inflammatory markers in blood samples</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Prior to ablation blood samples will be collected for determination of inflammatory parameters in a subsample of the study (neutrophil to lymphocyte ratio, TNF-alpha, fibrinogen, IL-2, IL6, IL-8, C-reactive protein). At 3 and 12 months of follow-up the determination of these parameters will be repeated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life measured by SF-36 questionnaire</measure>
    <time_frame>mean follow up of 2 years</time_frame>
    <description>Change in quality of life during the follow up measured by SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Mediterranean diet plus extra virgin olive oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no specific diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mediterranean diet plus extra virgin olive oil</intervention_name>
    <description>The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet</description>
    <arm_group_label>Mediterranean diet plus extra virgin olive oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic paroxysmal AF (with evidence of more than one symptomatic
             episode in the last year and at least one documented episode) upon whom catheter
             ablation is performed.

          -  Patients with persistent symptomatic AF upon whom catheter ablation is performed.

        Exclusion Criteria:

          -  Serious medical condition that prevents dietary intervention (gastrointestinal disease
             with intolerance to fats, advanced malignancy, neurological, psychiatric or severe
             endocrine disease)

          -  Any other pathology or medical condition that limits survival to less than one year;
             Immunodeficiency or HIV-positive,

          -  Consumption of illegal drugs,

          -  Chronic alcoholism or total consumption of alcohol &gt;80 g/d

          -  Body mass index &gt; 40 kg/m 2,

          -  Difficulty or major inconvenience with changing dietary habits, inability to follow a
             style of Mediterranean diet, low probability of changing dietary habits according to
             the models of Prochaska and Diciemente (Nigg, 1999)

          -  History of food allergy or hypersensitivity to any component of EVOO

          -  Participation in a clinical trial carried out with drugs or use of a drug in
             experimental state during the year prior to inclusion

          -  Institutionalized patients for chronic treatment, with lack of autonomy and with
             inability to perform the clinical follow-up,

          -  Impossibility of telephone contact

          -  Patients with acute infection or inflammatory process (e.g. pneumonia) may be included
             in the study three months after the resolution of the infectious symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Martinez González, MD, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Almendral Garrote, MD, PhD, FESC</last_name>
    <role>Study Director</role>
    <affiliation>Fundación HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Barrio Lopez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teresa Barrio-López, MD, PhD</last_name>
    <email>terebarriol@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesus Almendral, MD, PhD, FESC</last_name>
    <email>almendral@secardiologia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Teresa Barrio Lopez</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Barrio-López, MD,PhD</last_name>
      <phone>+34 655298270</phone>
      <email>terebarriol@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jesús Almendral, MD,PhD, FESC</last_name>
      <phone>+34 609380942</phone>
      <email>almendral@secardiologia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel A Martinez-González, MD, PhD,MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Almendral Garrote, MD, PhD,FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Barrio López, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Tercedor Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose J Jimenez Moleón, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Ramos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Ruiz-Canela, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teresa Barrio López</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Barrio Lopez, MD, PhD</last_name>
      <phone>+34 655298270</phone>
      <email>terebarriol@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jesus Almendral, MD, PhD, FESC</last_name>
      <phone>+34 609380942</phone>
      <email>almendral@secardiologia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Miguel A Martinez-González, MD, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Ruiz-Canela, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Almendral Garrote, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Barrio López, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Tercedor Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose J Jimenez Moleón, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Ramos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Martínez-González MÁ, Toledo E, Arós F, Fiol M, Corella D, Salas-Salvadó J, Ros E, Covas MI, Fernández-Crehuet J, Lapetra J, Muñoz MA, Fitó M, Serra-Majem L, Pintó X, Lamuela-Raventós RM, Sorlí JV, Babio N, Buil-Cosiales P, Ruiz-Gutierrez V, Estruch R, Alonso A; PREDIMED Investigators. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevención con Dieta Mediterránea) trial. Circulation. 2014 Jul 1;130(1):18-26. doi: 10.1161/CIRCULATIONAHA.113.006921. Epub 2014 Apr 30.</citation>
    <PMID>24787471</PMID>
  </results_reference>
  <results_reference>
    <citation>Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4;368(14):1279-90. doi: 10.1056/NEJMoa1200303. Epub 2013 Feb 25. Erratum in: N Engl J Med. 2014 Feb 27;370(9):886.</citation>
    <PMID>23432189</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>February 12, 2017</last_update_submitted>
  <last_update_submitted_qc>February 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de investigación HM</investigator_affiliation>
    <investigator_full_name>Teresa Barrio</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Mediterranean Diet</keyword>
  <keyword>Extra Virgin Olive Oil</keyword>
  <keyword>Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

